Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer

被引:210
作者
Michalides, R
Griekspoor, A
Balkenende, A
Verwoerd, D
Janssen, L
Jalink, K
Floore, A
Velds, A
van 't Veer, L
Neefjes, J
机构
[1] Netherlands Canc Inst, Dept Tumor Biol, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Cell Biol, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Expt Therapy, NL-1066 CX Amsterdam, Netherlands
[4] Netherlands Canc Inst, Cent Microarray Facil, NL-1066 CX Amsterdam, Netherlands
关键词
D O I
10.1016/j.ccr.2004.05.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Using a novel approach that detects changes in the conformation of ER(x, we studied the efficacy of anti-estrogens to inactivate ER(x under different experimental conditions. We show that phosphorylation of serine-305 in the hinge region of ERalpha by protein kinase A (PKA) induced resistance to tamoxifen. Tamoxifen bound but then failed to induce the inactive conformation, invoking ERalpha-dependent transactivation instead. PKA activity thus induces a switch from antagonistic to agonistic effects of tamoxifen on ERalpha. In clinical samples, we found that downregulation of a negative regulator of PKA, PKA-Rlalpha, was associated with tamoxifen resistance prior to treatment. Activation of PKA by downregulation of PKA-Rlalpha converts tamoxifen from an ERa inhibitor into a growth stimulator, without any effect on ICI 182780 (Fulvestrant).
引用
收藏
页码:597 / 605
页数:9
相关论文
共 40 条
[1]   Endocrine-responsive breast cancer and strategies for combating resistance [J].
Ali, S ;
Coombes, RC .
NATURE REVIEWS CANCER, 2002, 2 (02) :101-+
[2]   Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells [J].
Bindels, EMJ ;
Lallemand, F ;
Balkenende, A ;
Verwoerd, D ;
Michalides, R .
ONCOGENE, 2002, 21 (53) :8158-8165
[3]   Stable suppression of tumorigenicity by virus-mediated RNA interference [J].
Brummelkamp, TR ;
Bernards, R ;
Agami, R .
CANCER CELL, 2002, 2 (03) :243-247
[4]  
CANNEY PA, 1987, LANCET, V1, P36
[5]  
Chen DS, 1999, MOL CELL BIOL, V19, P1002
[6]  
Forbes John F., 1997, Seminars in Oncology, V24, P5
[7]   Estrogen receptor variants [J].
Hopp, TA ;
Fuqua, SAW .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1998, 3 (01) :73-83
[8]  
HORDIJK PL, 1994, J BIOL CHEM, V269, P3534
[9]   Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment [J].
Howell, A ;
Robertson, JFR ;
Albano, JQ ;
Aschermannova, A ;
Mauriac, L ;
Kleeberg, UR ;
Vergote, I ;
Erikstein, B ;
Webster, A ;
Morris, C .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3396-3403
[10]  
HOWELL A, 1995, LANCET, V345, P989, DOI 10.1016/S0140-6736(95)91156-1